<?xml version='1.0' encoding='utf-8'?>
<document id="27128001"><sentence text="The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans." /><sentence text="In vitro data suggest that alisporivir is a substrate and inhibitor of CYP3A4 and P-gp" /><sentence text=" Hence, the potential for drug-drug interactions when alisporivir is co-administered with CYP3A4 and/or P-gp inhibitors such as ketoconazole, azithromycin and CYP3A4 inducers such as rifampin were evaluated in three separate clinical studies"><entity charOffset="128-140" id="DDI-PubMed.27128001.s3.e0" text="ketoconazole" /><entity charOffset="142-154" id="DDI-PubMed.27128001.s3.e1" text="azithromycin" /><entity charOffset="183-191" id="DDI-PubMed.27128001.s3.e2" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.27128001.s3.e0" e2="DDI-PubMed.27128001.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27128001.s3.e0" e2="DDI-PubMed.27128001.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27128001.s3.e0" e2="DDI-PubMed.27128001.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27128001.s3.e1" e2="DDI-PubMed.27128001.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27128001.s3.e1" e2="DDI-PubMed.27128001.s3.e2" /></sentence><sentence text=" Co-administration with ketoconazole (a strong CYP3A4 inhibitor) increased the Cmax , AUC and terminal elimination half-life of alisporivir by approximately two-, eight- ,and threefold, respectively"><entity charOffset="24-36" id="DDI-PubMed.27128001.s4.e0" text="ketoconazole" /></sentence><sentence text=" Co-administration with azithromycin (a putative weak CYP3A4 inhibitor and substrate) had no impact on the Cmax and AUC of alisporivir"><entity charOffset="24-36" id="DDI-PubMed.27128001.s5.e0" text="azithromycin" /></sentence><sentence text=" Rifampin (a CYP3A4 inducer) caused an approximate 90% reduction in alisporivir Cmax and AUC and a fourfold reduction in alisporivir terminal elimination half-life"><entity charOffset="1-9" id="DDI-PubMed.27128001.s6.e0" text="Rifampin" /></sentence><sentence text=" Alisporivir as an inhibitor of CYP3A4 caused a 39% increase in azithromycin exposure"><entity charOffset="1-12" id="DDI-PubMed.27128001.s7.e0" text="Alisporivir" /><entity charOffset="64-76" id="DDI-PubMed.27128001.s7.e1" text="azithromycin" /><pair ddi="false" e1="DDI-PubMed.27128001.s7.e0" e2="DDI-PubMed.27128001.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27128001.s7.e0" e2="DDI-PubMed.27128001.s7.e1" /></sentence><sentence text=" The results from these studies establish alisporivir as a sensitive CYP3A4 substrate in vivo" /><sentence text=" Consequently, co-administered potent CYP3A4 inhibitors and inducers are likely to cause clinically significant changes in the exposure to alisporivir" /><sentence text="" /></document>